ANABV — AnaptysBio Share News
0.000.00%
Last trade - 00:00- $1.94bn
- $1.91bn
- $234.60m
U.S. RESEARCH ROUNDUP-GE Vernova, NVR, ServiceNow
U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy, MongoDB
U.S. STOCKS ON THE MOVE-Boeing, GlobalFoundries, Tesla
AnaptysBio rises after H.C. Wainwright upgrades to 'buy' on arthritis drug progress
Brief: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
AnaptysBio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: AnaptysBio Q1 Net Income USD -39.329 Million
Brief: AnaptysBio Q4 Net Income USD -21.784 Million
U.S. STOCKS ON THE MOVE-Chefs' Warehouse, Aptose Biosciences, Electromed
AnaptysBio climbs on arthritis drug trial data
Brief: Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial
Brief: Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis
Brief: Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab
U.S. RESEARCH ROUNDUP- Amazon, Mastercard, Tesla
U.S. STOCKS ON THE MOVE-Gold miners, Tesla, ADM
AnaptysBio slumps after abandoning eczema drug development
AnaptysBio to abandon eczema drug development after mid-stage trial failure (updated)
AnaptysBio to abandon eczema drug development after mid-stage trial failure (updated)
Brief: Anaptys Announces Phase 2B Trial Of ANB032, A BTLA Agonist, Did Not Meet Endpoints